PT2311848E - Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano - Google Patents
Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humanoInfo
- Publication number
- PT2311848E PT2311848E PT100062272T PT10006227T PT2311848E PT 2311848 E PT2311848 E PT 2311848E PT 100062272 T PT100062272 T PT 100062272T PT 10006227 T PT10006227 T PT 10006227T PT 2311848 E PT2311848 E PT 2311848E
- Authority
- PT
- Portugal
- Prior art keywords
- hcmv
- codon
- antigens
- optimized
- encoding
- Prior art date
Links
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000024697 human cytomegalovirus infection Diseases 0.000 title 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 239000013612 plasmid Substances 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000005457 optimization Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43554902P | 2002-12-23 | 2002-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2311848E true PT2311848E (pt) | 2013-10-03 |
Family
ID=32682258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100062272T PT2311848E (pt) | 2002-12-23 | 2003-12-19 | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
Country Status (13)
Country | Link |
---|---|
US (5) | US7410795B2 (pt) |
EP (2) | EP2311848B1 (pt) |
JP (2) | JP2006511221A (pt) |
AT (1) | ATE471335T1 (pt) |
AU (1) | AU2003301148A1 (pt) |
CA (2) | CA2508228C (pt) |
DE (1) | DE60333035D1 (pt) |
DK (1) | DK2311848T3 (pt) |
ES (1) | ES2429338T3 (pt) |
HK (1) | HK1152945A1 (pt) |
PT (1) | PT2311848E (pt) |
SI (1) | SI2311848T1 (pt) |
WO (1) | WO2004058166A2 (pt) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
ATE549032T1 (de) * | 1999-03-26 | 2012-03-15 | Vical Inc | Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen |
AU2003278776A1 (en) * | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
EP1578193A4 (en) * | 2002-12-23 | 2011-06-15 | Vical Inc | FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES |
AU2003301148A1 (en) * | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US7381422B2 (en) * | 2002-12-23 | 2008-06-03 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
EP1607485A1 (en) * | 2004-06-14 | 2005-12-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for quantifying VEGF121 isoform in a biological sample |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
CN1307423C (zh) * | 2005-01-08 | 2007-03-28 | 王明丽 | 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒 |
JP2006223194A (ja) * | 2005-02-17 | 2006-08-31 | Tosoh Corp | スタニオカルシン1(STC1)mRNAの測定方法 |
EP1851238A4 (en) * | 2005-02-24 | 2008-12-31 | Univ Massachusetts | FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF |
US9303080B2 (en) | 2006-01-13 | 2016-04-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
WO2008051285A2 (en) | 2006-04-01 | 2008-05-02 | Medical Service Consultation International, Llc | Methods and compositions for detecting fungi and mycotoxins |
WO2008121992A2 (en) * | 2007-03-30 | 2008-10-09 | Research Foundation Of State University Of New York | Attenuated viruses useful for vaccines |
WO2009005917A2 (en) * | 2007-05-29 | 2009-01-08 | Vical Incorporated | Methods of treating measles infectious disease in mammals |
US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
CN102123732A (zh) | 2008-06-20 | 2011-07-13 | 杜克大学 | 用于引发免疫应答的组合物,方法及试剂盒 |
WO2010014567A2 (en) * | 2008-08-01 | 2010-02-04 | Merck & Co., Inc. | Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof |
US20100068718A1 (en) | 2008-08-22 | 2010-03-18 | Hooper Dennis G | Methods and Compositions for Identifying Yeast |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
EP3178490B1 (en) | 2009-07-15 | 2022-04-20 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
JP5833443B2 (ja) * | 2009-08-29 | 2015-12-16 | 株式会社バイオメッドコア | 抗原特異的t細胞誘導能測定法 |
US8962251B2 (en) | 2009-10-08 | 2015-02-24 | Medical Service Consultation International, Llc | Methods and compositions for identifying sulfur and iron modifying bacteria |
WO2011053798A2 (en) | 2009-10-30 | 2011-05-05 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
WO2011100443A1 (en) * | 2010-02-11 | 2011-08-18 | Intelligent Medical Devices, Inc. | Oligonucleotides relating to clostridium difficile genes encoding toxin b, toxin a, or binary toxin |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
BR112013000391B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição de emulsão catiônica de óleo em água e seu uso |
SI2590626T1 (sl) | 2010-07-06 | 2016-01-29 | Glaxosmithkline Biologicals S.A. | Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA |
LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
CA2804492A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
BR112013000392B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
US9127321B2 (en) * | 2010-10-06 | 2015-09-08 | The Translational Genomics Research Institute | Method of detecting Coccidioides species |
US20140030292A1 (en) | 2010-10-11 | 2014-01-30 | Novartis Ag | Antigen delivery platforms |
WO2012103361A1 (en) | 2011-01-26 | 2012-08-02 | Novartis Ag | Rsv immunization regimen |
CN103842374A (zh) | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | 融合前的rsv f抗原 |
EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
JP6059220B2 (ja) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | 核酸を含む水中油型エマルジョン |
TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製cmv |
BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
CN104271745A (zh) | 2011-11-11 | 2015-01-07 | 变异生物技术公司 | 用于治疗巨细胞病毒的组合物和方法 |
BR112014023913B1 (pt) | 2012-03-27 | 2022-08-09 | Variation Biotechnologies Inc | Métodos para detecção de anticorpos neutralizantes de anticitomegalovírus |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
EP2872183B1 (en) | 2012-07-11 | 2018-09-26 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
WO2014055624A1 (en) | 2012-10-02 | 2014-04-10 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods relating to dna-sensing pathway related conditions |
MX2015008847A (es) | 2013-01-10 | 2015-10-30 | Novartis Ag | Composiciones inmunogenicas de virus de influenza y usos de las mismas. |
EP2765137A1 (en) | 2013-02-07 | 2014-08-13 | Sanofi Pasteur | Induction of cross-reactive cellular response against rhinovirus antigens |
AU2014237801B2 (en) | 2013-03-15 | 2017-08-10 | Applied Food Biotechnology, Inc. | Feline bitter taste receptors and methods |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
WO2017011773A2 (en) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
TN2018000152A1 (en) | 2015-10-22 | 2019-10-04 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11197936B2 (en) | 2016-07-08 | 2021-12-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of disorders and diseases involving RDH12 |
EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS |
US20190314486A1 (en) | 2016-10-21 | 2019-10-17 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
JP7235676B2 (ja) | 2017-05-17 | 2023-03-08 | ザ ジェネラル ホスピタル コーポレイション | 結節性硬化症の遺伝子治療 |
EP3638207A1 (en) | 2017-06-15 | 2020-04-22 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
CN111655715A (zh) | 2018-01-29 | 2020-09-11 | 默沙东公司 | 稳定化的rsv f蛋白及其用途 |
CN109082413B (zh) * | 2018-09-18 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
AU2021219652A1 (en) | 2020-02-14 | 2022-08-18 | Merck Sharp & Dohme Llc | HPV vaccine |
AU2021264465A1 (en) | 2020-04-27 | 2022-12-15 | University Of Iowa Research Foundation | Compositions and methods for the treatment of cystic fibrosis |
EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
AU2021337493A1 (en) | 2020-09-04 | 2023-05-18 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
WO2022051024A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
CA3173941A1 (en) | 2020-09-04 | 2022-03-10 | Emily VOIGT | Live-attenuated rna hybrid vaccine technology |
TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
JP2024516575A (ja) | 2021-04-16 | 2024-04-16 | ジェネンテック, インコーポレイテッド | 最適化されたtlr7リガンド及びその使用 |
CA3223219A1 (en) | 2021-06-14 | 2022-12-22 | Bridgebio Gene Therapy Research, Inc. | Gene therapy for tuberous sclerosis |
WO2023017098A2 (en) | 2021-08-11 | 2023-02-16 | King's College London | Compositions and methods for improved treatment of disorders affecting the central nervous system |
US20230118665A1 (en) | 2021-08-19 | 2023-04-20 | Merck Sharp & Dohme Llc | Novel thermostable lipid nanoparticle and methods of use thereof |
WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
WO2024068898A1 (en) | 2022-09-30 | 2024-04-04 | Centre National De La Recherche Scientifique | Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
US6133433A (en) * | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
US6242567B1 (en) * | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
US6162620A (en) | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
US5124440A (en) * | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
DE68929478T2 (de) * | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5837693A (en) | 1995-03-24 | 1998-11-17 | The Regents Of The University Of California | Intravenous hormone polypeptide delivery by salivary gland expression |
US5885971A (en) | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US5721354A (en) * | 1995-03-31 | 1998-02-24 | Aviron | Human cytomegalovirus DNA sequences |
US5800981A (en) * | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
US6020481A (en) | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
WO1997040165A1 (en) * | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
FR2753512B1 (fr) * | 1996-09-19 | 1998-12-31 | Sachs Ind Sa | Chaine de transmission notamment pour cycle |
US6156317A (en) * | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
CA2296067C (en) * | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
KR100239879B1 (ko) * | 1997-11-05 | 2000-02-01 | 김상조 | 간암 예방 및 치료용 생약제 |
JP3253590B2 (ja) * | 1998-08-31 | 2002-02-04 | シャープ株式会社 | ハーフトーンマスクの製造方法 |
ATE549032T1 (de) * | 1999-03-26 | 2012-03-15 | Vical Inc | Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen |
FR2804028B1 (fr) | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
US6835383B2 (en) * | 2000-03-23 | 2004-12-28 | City Of Hope | Protein kinase deficient, immunologically active CMVpp65 mutants |
EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
DE60026199T2 (de) | 2000-05-18 | 2006-11-23 | Geneart Ag | Synthetische Gene für gagpol und deren Verwendungen |
WO2002000844A2 (en) * | 2000-06-23 | 2002-01-03 | Merck & Co., Inc. | Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
US20020110567A1 (en) * | 2000-08-10 | 2002-08-15 | Volker Gerdts | In utero oral nucleic acid immunization |
AU2003301148A1 (en) * | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20050283146A1 (en) | 2004-06-17 | 2005-12-22 | Lentz David J | Thermally extended spiral cryotip for a cryoablation catheter |
-
2003
- 2003-12-19 AU AU2003301148A patent/AU2003301148A1/en not_active Abandoned
- 2003-12-19 CA CA2508228A patent/CA2508228C/en not_active Expired - Fee Related
- 2003-12-19 SI SI200332305T patent/SI2311848T1/sl unknown
- 2003-12-19 ES ES10006227T patent/ES2429338T3/es not_active Expired - Lifetime
- 2003-12-19 DK DK10006227.2T patent/DK2311848T3/da active
- 2003-12-19 US US10/738,986 patent/US7410795B2/en not_active Expired - Fee Related
- 2003-12-19 EP EP10006227.2A patent/EP2311848B1/en not_active Expired - Lifetime
- 2003-12-19 DE DE60333035T patent/DE60333035D1/de not_active Expired - Lifetime
- 2003-12-19 WO PCT/US2003/040685 patent/WO2004058166A2/en active Application Filing
- 2003-12-19 PT PT100062272T patent/PT2311848E/pt unknown
- 2003-12-19 EP EP03814236A patent/EP1587816B1/en not_active Expired - Lifetime
- 2003-12-19 JP JP2004563851A patent/JP2006511221A/ja active Pending
- 2003-12-19 CA CA2756797A patent/CA2756797C/en not_active Expired - Fee Related
- 2003-12-19 AT AT03814236T patent/ATE471335T1/de not_active IP Right Cessation
-
2007
- 2007-08-17 US US11/892,020 patent/US7888112B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 JP JP2010101904A patent/JP5129292B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-25 US US13/013,752 patent/US8278093B2/en not_active Expired - Fee Related
- 2011-07-06 HK HK11106976.2A patent/HK1152945A1/xx not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/525,814 patent/US8673317B2/en not_active Expired - Fee Related
-
2014
- 2014-02-10 US US14/176,813 patent/US9180162B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2311848B1 (en) | 2013-07-03 |
JP2006511221A (ja) | 2006-04-06 |
US8278093B2 (en) | 2012-10-02 |
US20110177124A1 (en) | 2011-07-21 |
AU2003301148A8 (en) | 2004-07-22 |
US7888112B2 (en) | 2011-02-15 |
DE60333035D1 (de) | 2010-07-29 |
EP1587816A4 (en) | 2006-06-07 |
HK1152945A1 (en) | 2012-03-16 |
US9180162B2 (en) | 2015-11-10 |
EP2311848A1 (en) | 2011-04-20 |
US20080085870A1 (en) | 2008-04-10 |
ATE471335T1 (de) | 2010-07-15 |
WO2004058166A2 (en) | 2004-07-15 |
US20140186382A1 (en) | 2014-07-03 |
CA2508228A1 (en) | 2004-07-15 |
US8673317B2 (en) | 2014-03-18 |
EP1587816B1 (en) | 2010-06-16 |
AU2003301148A1 (en) | 2004-07-22 |
JP5129292B2 (ja) | 2013-01-30 |
CA2756797C (en) | 2015-05-05 |
US20040209241A1 (en) | 2004-10-21 |
ES2429338T3 (es) | 2013-11-14 |
CA2756797A1 (en) | 2004-07-15 |
US20130017217A1 (en) | 2013-01-17 |
EP1587816A2 (en) | 2005-10-26 |
JP2010227101A (ja) | 2010-10-14 |
DK2311848T3 (da) | 2013-10-14 |
WO2004058166A3 (en) | 2005-06-16 |
SI2311848T1 (sl) | 2013-11-29 |
US7410795B2 (en) | 2008-08-12 |
CA2508228C (en) | 2013-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1152945A1 (en) | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection | |
KR101650364B1 (ko) | 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질 | |
US10227385B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
ES2224655T3 (es) | Vacuna antiviral recombinante de la encefalitis equina venezolana. | |
AU734443B2 (en) | Vaccines | |
Schneeweiss et al. | A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII | |
CN105039266A (zh) | 复制缺陷型黄病毒疫苗和疫苗载体 | |
IL134341A0 (en) | Compositions for inducing an immune response containing an hpv protein antigen | |
EP1799255A1 (en) | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens | |
US20230234992A1 (en) | Modified betacoronavirus spike proteins | |
DK263390D0 (da) | Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression | |
WO2004024067A3 (en) | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection | |
CN103442729A (zh) | 疟疾的治疗和预防 | |
ES2239758T3 (es) | Glicoproteina de fusion de cmvh y vhs. | |
EP0538341B1 (en) | Ehv-4 glycoprotein vaccine | |
JP2023523423A (ja) | SARS-CoV-2に対するワクチン及びその調製物 | |
Toussaint et al. | Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8 | |
Zakhartchouk et al. | Optimization of a DNA vaccine against SARS | |
CA3170674A1 (en) | Novel salmonella-based coronavirus vaccine | |
Drew et al. | A comparison of DNA vaccines expressing the 45W, 18k and 16k host-protective antigens of Taenia ovis in mice and sheep | |
CY1114437T1 (el) | Εμβολια με βαση πολυνουκλεοτιδιο βελτιστοποιημενου κωδικονιου εναντι μολυνσης ανθρωπινου κυτομεγαλοϊου | |
BRPI0720319A2 (pt) | "ácido nucléico isolado, polipeptídeo isolado, vetor de expressão, célula hospedeira, método para aprodução de um poliptídeo de fusão, partícula do vírus de mosaico do bambu quimérico, método para a produção de uma partícula do vírus de mosaico do bambu quimérico, composição imunogênica e método para a indução de uma imunoresposta em um indivíduo" | |
ES2900364T3 (es) | Glicoproteína G truncada del virus del herpes simple tipo 2 | |
WO2022055375A1 (es) | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante | |
Durmanova et al. | Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice |